Navigation Links
Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
Date:10/1/2009

apies and chemotherapy in a number of tumor types.

"We believe that MM-121 has the potential to serve as an important new treatment for multiple forms of cancer," said Robert Mulroy, President and Chief Executive Officer of Merrimack. "We are pleased to partner with sanofi-aventis, a premier, global pharmaceutical company with broad oncology expertise. Together, we hope to work with the international research community to accelerate the development of MM-121 for the benefit of patients."

Merrimack developed MM-121 after identifying the importance of ErbB3 through its Network Biology approach, a fully integrated drug discovery and development technique that combines biology, engineering, and computational modeling to better understand the underlying complexity of disease pathways. The information derived from Network Biology informs the strategic decisions guiding early pharmaceutical discovery as well as helping to advance candidates through pre-clinical, clinical development and towards commercialization.

The effectiveness of the license and collaboration is subject to antitrust clearance under the Hart-Scott-Rodino

Antitrust Improvements Act and other customary regulatory approvals.

About Merrimack

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111 are currently in Phase 1 clinical development. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and well tolerated therapeutics. MM-121 and MM-111 are investigational drugs
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)...  Decision Resources Group finds that the market for interventional ... remain relatively stagnant at a value of around $80 million ... intervention (PCI) volumes are growing faster in Canada ... the United States and Europe ... increase in penetration of PCI procedures relative to coronary artery ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
Breaking Medicine Technology:The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2
... 12, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... on August 29, 2011, as Vice President, Finance and Chief ... Arena for over 13 years before departing in March to ... a valuable leader who has been a key contributor to ...
... 2011 5 modules - 2 weeks - ... to announce that the Stability Testing Online Training Course is proving ... ,The secret behind the Stability testing Online Training Course ... is its user-friendly format which allows flexible and interactive high standard, ...
Cached Medicine Technology:Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3Stability Testing Course is Taking the Online Training Format by Storm! 2
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July ... pregnancy may be more likely to have children with asthma ... that, compared with children born from mothers of normal weight, ... up to 20 to 30 percent higher odds of asthma," ... pediatrics at Children,s Hospital of Pittsburgh. Forno,s team also ...
(Date:7/22/2014)... 2014) The American Society of Hematology (ASH) will ... of Medicine, and Robert P. Hebbel, MD, of the ... Beutler Lecture and Prize for their significant research advances ... Ernest Beutler Lecture, named for the late Ernest Beutler, ... more than 50 years, is a two-part lectureship that ...
(Date:7/22/2014)... of the Clean Plate Club you eat pretty much ... A new Cornell University study shows that the average ... his or her plate. "If you put it ... Wansink Ph.D., author of the forthcoming book, Slim by Design, ... Brand Lab. , Wansink and co-author Katherine Abowd Johnson analyzed ...
(Date:7/22/2014)... disease, Dr. Ross Feldman says women are often in the ... men,s-only disease, however, data has shown that post-menopausal women are ... are less likely to be adequately diagnosed and treated. New ... British Journal of Clinical Pharmacology brings to light ... to identify which women are more prone to heart disease. ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:Gene variant identified as a heart disease risk factor for women 2
... February issue of PNAS that understanding and treating cholesterol-related ... discovery of a receptor in the cells of mice ... during a study of cerebrotendinous xanthomatosis (CTX), a rare ... They said that Pregnane X receptor (PXR)// is present ...
... curvature of the spine diagnosed after the age ten, ... to earlier belief that the condition increases mortality rates ... related to the curvature. Researchers from the University of ... with LIS appear to experience only little physical// impairment ...
... to be launched by researchers from the UK and Netherlands ... with cancer. The research will be led by Dr. Julian ... Dr. René Bernards of the Netherlands Cancer Institute. This research ... and will have scientists looking at nearly 10,000 genes, inactivating ...
... journal, Cancer Cell reported that scientists have discovered why some ... others. Researchers have found that high levels of a specific ... drugs such as Taxol, which are used to treat a ... the// researchers focused on a molecule called AURORA-A which is ...
... has shown that those who smoke face the highest ... However, researchers added that more studies are needed before ... of cross-sectional data obtained from the US National Household ... from 1994 to 1996) was conducted. A total// of ...
... from the Department of Human Services at the University ... elevated levels of abdominal visceral fat are associated with ... was also found to be a primary determinant in ... investigators assessed// plasma lipids and lipoproteins and their relationships ...
Cached Medicine News:Health News:Cancer gene mystery to be cracked! 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: